DRI approaches $1bn target for Fund III
The pharmaceutical royalties-focused firm is expected to close Fund III above target after coming to market in mid-2012.
The pharmaceutical royalties-focused firm is expected to close Fund III above target after coming to market in mid-2012.
Copyright PEI Media
Not for publication, email or dissemination